For full details of each session, please view the event guide.

8:30 am

Morning Coffee

9:00 am Chair’s Opening Remarks

3D/Ex Vivo Models

9:05 am Improving the Safety Predictability of IO Modalities with Organ on Chip (OoC) Models


  • Incorporating new OoC models in IO workflow: Key aspects to consider
  • How to use OoC for Efficacy Models in IO
  • Challenges in safety prediction in IO and how OoC can help
  • High level overview of the regulatory status regarding using OoC based IO data in submission

9:35 am Round Table Discussions:


Discover multiple perspectives on the key issues in preclinical development. Join a roundtable discussion that has been specifically designed to enable you to leave with insights that you can immediately implement into your preclinical model strategies

Challenges in the scale-up and wider adoption of organoid models

How familiar should preclinical scientists be with Regulatory concepts? What should be considered in preclinical study design

Will isoform-specific detection and targeting in different tumour subtypes result into a further developed personalized Medicine?

10:05 am Enabling patient-centric cancer R&D with primary tissues and Pharmacoscopy®


  • Primary tissue are as close as one can get to an actual patient in preclinical R&D
  • Quantifying drug action in these complex samples, however, is analytically very challenging
  • With Pharmacoscopy® we can interrogate drug activity in live human tumour tissues at the single cell level at scale and with demonstrated clinical translatability

10:20 am

Speed Networking

10:50 am

Morning Coffee

In Vitro Assays

11:20 am Panel Discussion: To What Extent Will Ex-Vivo Platform Replace In-Vivo Models From Technical, Ethical, and Regulatory Standpoints?

  • Pelin Candarlioglu Investigator - Complex in Vitro Models, GSK
  • David Barbie Associate Director, Dana Faber cancer institute
  • Anthony Letai Professor of Medicine, Dana Faber cancer institute
  • Anita Seshire Head of Laboratory in Exploratory Cancer Research, Translational Innovation Platform Oncology, Merck & Co

12:00 pm RNA-Sequencing Analysis of Immunotherapy Response in Organotypic Tumor Spheroids

  • David Barbie Associate Director, Dana Faber cancer institute


  • Bulk RNA-sequencing (RNA-seq) uncovers dynamic responses to interferon-gamma versus PD- 1blockade in murine organotypic spheroids
  • Development of methods to extract cells and perform single cell RNAseq refines this analysis
  • These high resolution ex vivo functional studies help to uncover novel immunobiology

12:30 pm Improving Therapy and Stratification by Listening to Mitochondria

  • Anthony Letai Professor of Medicine, Dana Faber cancer institute


  • If you want your drug to work in cancer, it has to kill the cancer cell
  • Mitochondria decide whether or not the cancer cell dies via apoptosis
  • BH3 profiling predicts whether apoptosis will occur

1:00 pm Poster Session: Showcase your work live amongst industry pioneers through a series of short poster presentations

1:40 pm

Networking Lunch

Supporting Techniques in Evaluating Therapeutic Response

2:40 pm Imaging of PD-L1 in Head and Neck Cancer in Response to Oncolytic Virotherapy

3:10 pm PK/PD from Drug Discovery to Registration: An Industry Case Study

  • Sonya Chapman Senior PK/PD Project Leader , Eli Lilly and Company


  • PK/PD is a key tool in drug discovery and development
  • Pre-clinical PK/PD knowledge is continually informative through compound identification, dose projection, clinical study designs and drug registration
  • Establishing efficacious concentrations early helps to design molecules with high potential

3:40 pm Chair’s Closing Remarks

4:00 pm End of Day 2